anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
BACKGROUND: Cancer-related fatigue (CRF) is a common and debilitating symptom experienced by patients with advanced-stage cancer, especially those undergoing antitumor therapy. This study aimed to evaluate the efficacy and safety of Renshenguben (RSGB) oral solution, a ginseng-based traditional Chinese medicine, in alleviating CRF in patients with advanced hepatocellular carcinoma (HCC) receiving antitumor treatment.
METHODS: In this prospective, open-label, controlled, multicenter study, patients with advanced HCC at BCLC stage C and a brief fatigue inventory (BFI) score of ≥ 4 were enrolled. Participants were assigned to the RSGB group (RSGB, 10 mL twice daily) or the control group (with supportive care). Primary and secondary endpoints were the change in multidimensional fatigue inventory (MFI) score, and BFI and functional assessment of cancer therapy-hepatobiliary (FACT-Hep) scores at weeks 4 and 8 after enrollment. Adverse events (AEs) and toxicities were assessed.
RESULTS: A total of 409 participants were enrolled, with 206 assigned to the RSGB group. At week 4, there was a trend towards improvement, but the differences were not statistically significant. At week 8, the RSGB group exhibited a significantly lower MFI score (P < 0.05) compared to the control group, indicating improved fatigue levels. Additionally, the RSGB group showed significantly greater decrease in BFI and FACT-Hep scores at week 8 (P < 0.05). Subgroup analyses among patients receiving various antitumor treatments showed similar results. Multivariate linear regression analyses revealed that the RSGB group experienced a significantly substantial decrease in MFI, BFI, and FACT-Hep scores at week 8. No serious drug-related AEs or toxicities were observed.
CONCLUSIONS: RSGB oral solution effectively reduced CRF in patients with advanced HCC undergoing antitumor therapy over an eight-week period, with no discernible toxicities. These findings support the potential of RSGB oral solution as an adjunctive treatment for managing CRF in this patient population.
BACKGROUND: Mastectomy skin flap necrosis (SFN) is common following nipple-sparing mastectomy (NSM), but studies on its quality-of-life (QOL) impact are limited. We examined patient-reported QOL and satisfaction after NSM with/without SFN utilizing the BREAST-Q patient-reported outcome measure (PROM) survey.
PATIENTS AND METHODS: Patients undergoing NSM between April 2018 and July 2021 at our institution were examined; the BREAST-Q PROM was administered preoperatively, and at 6 months and 1 year postoperatively. SFN extent/severity was documented at 2-3 weeks postoperatively; QOL and satisfaction domains were compared between patients with/without SFN.
RESULTS: A total of 573 NSMs in 333 patients were included, and 135 breasts in 82 patients developed SFN (24% superficial, 56% partial thickness, 16% full thickness). Patients with SFN reported significantly lower scores in the satisfaction with breasts (p = 0.032) and psychosocial QOL domains (p = 0.009) at 6 months versus those without SFN, with scores returning to baseline at 1 year in both domains. In the "physical well-being-of-the-chest" domain, there was an overall decline in scores among all patients; however, there were no significant differences at any time point between patients with or without SFN. Sexual well-being scores declined for patients with SFN compared with those without at 6 months and also at 1 year, but this did not reach significance (p = 0.13, p = 0.2, respectively).
CONCLUSIONS: Patients undergoing NSM who developed SFN reported significantly lower satisfaction and psychosocial well-being scores at 6 months, which returned to baseline by 1 year. Physical well-being of the chest significantly declines after NSM regardless of SFN. Future studies with larger sample sizes and longer follow-up are needed to determine SFN's impact on long-term QOL.
Participants assigned to the waitlist-control condition will not immediately receive services. The no-treatment duration for these participants is yoked to the amount of time their respective NMT- and OT-condition participants receive services (5 weeks). After the wait period, these participants will then be randomized to receive either NMT, MST or OT sessions.
FIELD: technology of balsam agents. SUBSTANCE: invention relates to balsam agents based on oily-spirituous extracts of natural raw. Method involves extraction of ground propolis followed by separation of extract. Before extraction of propolis ground garlic is extracted additionally with ethyl alcohol at mass ratio 1:4 to an alcohol. Clear fraction of garlic extract is separated and used its for extraction of ground propolis at mass ratio 1:9 to garlic extract. Clear fraction of obtained extract is separated and mixed its with vegetable oil at ratio 1:10 to vegetable oil being the latter is cooled to 25 C and pasteurized preliminary. Alcohol and water vapors are removed by sublimation and obtained oily extract is matured for a week followed by its separation and sealing its clear fraction. EFFECT: stable property of an agent, broad pattern of an agent. 5 cl, 4 ex
All participants will receive 9 intradermal DC vaccines (three -bi-weekly (q2 weeks) for priming, monthly for additional 2-3 cycles during T cell expansion, and three bi-weekly during T cell engraftment), a single i.v. infusion of ex vivo expanded tumor-reactive T cells, and a i.v. single infusion of autologous HSCs.
Hemophilia A and B are congenital, recessive X-linked disorders caused by lack or deficiency of clotting factor VIII (FVIII) or IX (FIX), respectively. The severity of the disease depends on the reduction of levels of FVIII or FIX, which are determined by the type of the causative mutation in the genes encoding the factors (F8 and F9, respectively). The hallmark clinical characteristic, especially in untreated severe forms, is bleeding (spontaneous or after trauma) into major joints such as ankles, knees and elbows, which can result in the development of arthropathy. Intracranial bleeds and bleeds into internal organs may be life-threatening. The median life expectancy was \~30 years until the 1960s, but improved understanding of the disorder and development of efficacious therapy based on prophylactic replacement of the missing factor has caused a paradigm shift, and today individuals with hemophilia can look forward to a virtually normal life expectancy and quality of life.

Historically, hemophilia treatment has focused on replacement of the missing coagulation factor to achieve hemostasis. Treatment progressed from use of cryoprecipitate (FVIII replacement in HA) or fresh frozen plasma (FFP) to plasma-derived factor concentrates, allowing for early control of hemorrhage, home therapy and accessibility for the introduction of prophylaxis. Contamination of factor concentrate supply with human immunodeficiency virus and hepatitis C virus led to the unfortunate infection of most of the severe hemophilia population in the 1980s, necessitating development of improved methods to screen and inactivate viruses. These mechanisms include dry-heat, pasteurisation, solvent-detergent treatment, immunoaffinity purification and nanofiltration, although some risk from emerging infections remains. Recombinant factor therapies were introduced to address the concern for infection transmission but raised new challenges regarding the risk of inhibitor formation. The extended half-life (EHL) factor products are a result of engineering proteins for longer recovery times in persons with hemophilia (PwH), to reduce frequency of dosing for prophylax

-Factor VIII mimetic Emicizumab (Hemlibra, Genentech/Roche) is a first in-class humanised bispecific antibody substitution for HA designed to function as FVIIIa by binding one arm of the antibody to FIXa and the other arm to FX, accelerating activation of Fxa and propagating thrombin production. The application and incorporation of this novel approach using a SC antibody to prevent bleeding was outlined in a series of clinical trials (HAVEN) including PwHA with inhibitors, paediatric PwHA with inhibitors and PwHA without inhibitors. The bispecific antibody mechanism and half-life (˜28 days) overcomes the inhibitory alloantibody, limits the need for IV access and decreases infusion frequency. In HAVEN-1, males with severe HA and inhibitors aged ≥12 years received weekly prophylaxis (1·5 mg/kg) with emicizumab and had an 87% reduction in overall annualized bleeding rate (ABR)
Exercise remains a challenge to AP systems; more specifically, by the time exercise is detected it is often too late to avoid hypoglycemia without the ingestion of rapid carbohydrates or the use of rescue injections, such as glucagon. To this avail, the investigators propose to add a novel Model Predictive Control module to the proven USS system. This module is designed to compute insulin doses every 5 minutes that are designed to "optimally" maintain glycaemia around a target of 120mg/dL. The optimality is defined mathematically as minimizing deviations from basal rate injections and the distance between current and future (up to 2h) glycaemia from a physiologically feasible trajectory back down (or up) to a pre-specified target. Furthermore, the novel control system, labelled Multi Stage MPC or Ensemble MPC, accounts for a preset number of exercise scenarios during the prediction horizon, these scenarios being derived from the user historical record; this setup allows the control system to anticipate expected exercise bouts up to 2h in advance while maintaining the condition for optimal glycemic control.

By adding such module to a well validated system, the investigators expect an improvement in protection against hypoglycemia during and immediately after physical activity without increase in hyperglycemia. To demonstrate the feasibility of this approach, the novel anticipatory system will be compared to a naïve AP system during highly supervised hotel admissions with afternoon exercise. Participants will be asked to exercise regularly in the late afternoon during a month of data collection to generate the patterns to be anticipated.
The mood status of fatigue can impact daily activities. Dietary collagen peptides have been reported to be beneficial for health conditions. A randomized, double-blinded, placebo-controlled, parallel-group study investigated the effects of collagen peptides on mood status including fatigue, physical condition, and immunological status. The participants who were healthy but easily fatigued consumed active food containing collagen peptides (10 g/day) (n = 33) or placebo food (n = 33) for eight weeks. POMS® 2 was used to assess the perceived fatigue and other mood status. The primary outcome was the T-scores of Fatigue-Inertias at eight weeks. In addition, their physical condition and immunological parameters were evaluated. The data set was a per protocol set of 31 participants each in both groups. As for POMS® 2, the T-score of Fatigue-Inertias at eight weeks was significantly lower in the active group than in the placebo group (47.0 ± 7.4 versus 51.5 ± 9.0, p = 0.045). The T-score of Vigor-Activity was significantly higher in the active group than in the placebo group after eight weeks (53.9 ± 10.7 versus 47.3 ± 9.6, p = 0.002). Regarding the questionnaire on the physical condition, the Likert scale score on fatigue after a night's sleep at eight weeks was significantly lower in the active group than in the placebo group (median; 3.0 versus 4.0, p = 0.038). There were no significant differences in the measured values of immunological parameters. No safety-related issues were reported in this trial. The intake of collagen peptides (10 g/day) for eight weeks ameliorated the mood status of fatigue and vigor and increased the feeling of sleep restfulness. Dietary collagen peptides were efficient and safe nutritional ingredients for healthy but easily fatigued individuals.Clinical trial registry number and website: UMIN-CTR, UMIN000042291 https://center6.umin.ac.jp/cgi-open-bin/ctr/ctr_view.cgi?recptno=R000048280.
Patients who require placement of an epidural catheter to control postoperative pain and invasive blood pressure will be identified, allowing advanced monitoring using the MostCare Up® device. After identification, the objective of the study will be explained and their consent will be requested to collect the data after the intervention, recording the hemodynamic data before and after the initial bolus of local anesthetic administered: 0.25% levobupivacaine, the dose of which is calculated with the Takasaki formula: 0.05ml x weight (kg) x number of dermatomes to anesthetize.
Individuals that have been previously diagnosed with Pre-Diabetes. This group may include individuals with pre-diabetes that may be unaware of their condition. HbA1C values between 5.7% and 6.4%.
BACKGROUND: Available statistical data from 2015 show that 28% of pregnancies in developed countries end in cesarean section (CC). Discomfort associated with the scar after surgery is a common complication.
OBJECTIVES: This study aimed to evaluate the changes in the structure of the cesarean scar after the application of a scheme of manual therapy.
MATERIAL AND METHODS: The study included 15 women in the treatment group (TG) and 15 in the control group (CG). The scars were evaluated twice at 5-week intervals with the use of quantitative scales: the Vancouver Scar Scale (VSS), the Manchester Scar Scale (MSS) and the Patient and Observer Scar Assessment Scale (POSAS). During each examination, the scar was compared, using the specified criteria, to the physiological skin, i.e., the tissues directly bordering the incision. During therapy, 8 manual techniques were used during a 4-week program consisting of 30-minute sessions 3 times per week.
RESULTS: Patients in the TG showed a statistically significant improvement in all of the analyzed characteristics of the scar. A statistically significant difference was also observed between the results obtained during the 2nd examination (after the therapy) in the TG and the CG.
CONCLUSIONS: As a result of the therapy, the condition of the scar in the TG significantly improved. Onerous scar-related symptoms were alleviated. The vascularity, hyperpigmentation and distortion of the scar were reduced. The elasticity and pliability of the scar increased, and the height of the scar decreased. The texture, finish and contour of the scar improved. Obtained results suggest that manual therapy of the scar after CC should be a part of the treatment in women during the postpartum period.
PURPOSE:To obtain a new compound having an inhibiting activity to lipoxygenase enzyme and useful in treatment and alleviation for inflammatory, allergic and cardiovascular diseases. CONSTITUTION:A compound of formula I (R1 is H, 1-4C alkyl, etc.; A is unsubstituted alkynylene or alkynylene substituted with 1-4C alkyl, 2-4C alkenyl, etc.; Ar is phenyl or naphthyl ; B is H, aryl, etc.; M is H, aroyl, etc.), e.g. N- hydroxy-N-[4-(3-phenoxyphenyl)-3-butyn-2-yl]acetamide. The compound is obtained by reacting, e.g. a hydroxylamine of formula II with acetyl chloride in the presence of triethylamine in a solvent such as THF at 0 deg.C to ambient temperature to afford a diacyl compound of formula III and then selectively hydrolyzing the compound of the formula III, generally at -10 deg.C to ambient temperature using a base such as NaOH.
The invention discloses a traditional Chinese medicine stock solution mixture. The formula synthesis comprises: 180g of seaweed, 160g of dried orange peel, 800mg of cordyceps militaris, 190g of ampelopsis grossedentata tea, 180g of dendrobium, 160g of pummelo peel, 30g of red date, 90g of white poria, 16g of dried pawpaw seed, 15g of dried pineapple flower, 60g of hawthorn, 90g of astragalus, 80g of dried liquorice, 80g of mulberry, 20g of black fungus, 60g of dried ginger, 30g of wormwood and 90g of green tea. The preparation method comprises the following steps: decocting the raw materials in water for four times, mixing, filtering, and extracting twice by distillation. The curative effect is as follows: 1. the oral preparation can be used for treating symptoms caused by metabolic syndrome of human body, has no side effect, and is suitable for treating obesity, insomnia, alopecia, edema, gastritis, diabetes, hypertension, hyperglycemia, hyperlipidemia, gout, tumor, numbness, vertigo, halitosis, constipation, etc. 2. The external preparation has effects of sterilizing, diminishing inflammation, relieving itching and detumescence, has no harm to human skin, and is suitable for treating corner ulcer, oral ulcer, toothache, acne, nasopharyngitis, pruritus, wound inflammation, paronychia, onychomycosis, tinea pedis, bromhidrosis, foot odor, hemorrhoid, etc. The using method comprises the following steps: the oral administration is 30ml, the oral administration is divided into 2 times, the effect is achieved within one week, and the cure can be realized in one to two treatment courses; 2. can be applied for many times for external use, has effect in one day, and can be cured in three to five days.
BACKGROUND: Abnormal uterine bleeding (AUB) affects women of all ages and is one of the most common reasons for referral to a gynaecological clinic. Operative hysteroscopic procedures allow for a see-and-treat approach to AUB, and these techniques have been shown to be feasible and acceptable in the outpatient setting.
OBJECTIVE: To assess if there is an increase in pain scores for women who are undergoing an operative hysteroscopic procedure with Myosure LITE® (Hologic; mechanical hysteroscopic tissue removal system) compared to outpatient diagnostic hysteroscopy alone.
STUDY DESIGN: A prospective cohort study was performed. All participants attending the outpatient hysteroscopy clinic at Mercy Hospital for Women completed a pre-and post-procedure questionnaire. This included a visual analogue scale (VAS) for any pre-existing pain, anticipated pain, and actual pain experienced during procedure. Factors influencing overall satisfaction and willingness to attend again were also assessed. Data was entered into RedCap® for analysis. A difference in VAS of 10 mm or more was considered clinically significant. An alpha of p < 0.05 was assigned for statistical significance.
RESULTS: Between February 2020 and November 2022, 208 women underwent outpatient diagnostic hysteroscopy followed by an operative hysteroscopy with MyoSure®. To allow for standardisation of analgesia, only participants who had a cervical block before their Myosure® procedure were included for analysis (n = 111). There was statistical evidence (t(111) = 2.36, p = 0.02) of a lower mean VAS pain score for operative Myosure (36.5 mm, 95 % CI: 31.1-41.8 mm) compared to outpatient diagnostic hysteroscopy (44.1 mm, 95 % CI: 39.0-49.2 mm). The mean difference in VAS pain score was estimated as 7.7 mm (95 % CI: 1.2-14.1 mm) lower for Myosure compared to hysteroscopy. Given the threshold for clinical significance was considered as 10 mm difference in VAS, the variance in pain scores is under the likely clinically significant range. There was no significant difference in pain scores for diagnostic hysteroscopy with or without paracervical block (mean difference = 1.42; 95 % CI: -6.35 to 9.20). There was no association between pre-existing pain, and actual pain for hysteroscopy, or Myosure (p = 0.997 and p = 0.065 respectively). The anticipated pain score was weakly associated with actual pain during the operative Myosure procedure (p = 0.02), and with outpatient diagnostic hysteroscopy (p = 0.019).
CONCLUSION: Outpatient hysteroscopy procedures are generally well tolerated. The pain experience with operative Myosure was less than that reported during the diagnostic hysteroscopy by the same patient although this is unlikely of clinical significance. Importantly, Myosure was not more painful than the initial diagnostic procedure, and most patients were satisfied with the outcome and would choose to have the procedure again in an outpatient setting. This is in keeping with other studies which have shown a high degree of patient tolerance and satisfaction with this approach.
Schizophrenia is a devastating psychiatric disorder that has detrimental effects on a significant portion of the global population. Electroconvulsive therapy (ECT), as a safe and effective physical therapy for schizophrenia, has demonstrated the ability to rapidly improve both positive and negative symptoms. Despite being used to treat schizophrenia for over 80 years, the therapeutic mechanisms of ECT are still in the early stages of exploration. Evidence has suggested that immune inflammation contributes to the pathogenesis of schizophrenia by interacting with neurotransmitters, neurodevelopment, and neurodegeneration. Given the importance of ECT as a fast-acting physical therapy for schizophrenia, gaining a deeper understanding of the role of immune inflammation may lead to developing innovative therapeutic approaches. This review summarized existing research that examined changes in peripheral inflammation following ECT in schizophrenia patients, and the effects of electroconvulsive stimulation (ECS) on neuroinflammation in animal studies.
POWERS (Personalized Online Weight and Exercise Response System) platform is a novel, multifocal-centered tailored intervention utilizing an innovative online tool designed to facilitate improvements in physical activity and nutritional behaviors. Aim 1 of this protocol is to customize the POWERS platform, demonstrated effective in previous research, for adults with intellectual disability (ID) and their caregivers to be referred to as POWERSforID. The POWERSforID intervention is designed to achieve weight loss and improve specific health markers while respecting and supporting the needs of the participants with ID as well as their caregivers. Aim 2 of the project is to conduct a pilot study to assess the usability and feasibility of the POWERSforID system and intervention with 5 adults with ID and their caregiver and improve the system based on pilot data. Aim 3 of the protocol is to conduct a randomized controlled trial (RCT) to examine the effect of POWERSforID on educating and coaching caregivers about nutrition and exercise and thus improving health status and reducing body weight in obese adults with ID. The investigators hypothesize that the obese participants in the intervention group (POWERSforID) will evidence significantly greater weight loss and improved health status (i.e. lower waist circumference, blood pressure, decreased body fat percentage, and improved blood lipids) compared to a control group. The investigators also hypothesize that both adults with ID and their caregivers will demonstrate improved knowledge, attitudes, and self-efficacy related to diet and exercise.
A dialysis soln. for use with artificial kidneys contains at most 0.2 mMol/l la and 5-55 mMol/l citrate ions and 130-165 mMol/l Na ions. A device for dialysis treatment with artificial kidneys consists of a dialysis cell (3), a conveyor pump (8) for the patients blood and a conveyor pump (9) for the dialysate soln. A dosing pump (6) is situated in pipe (15) for recycling blood after the dialysis cell (3). This pump adds Ca2+ and/or Mg2+ ions from a container to the patients blood. USE/AVANTAGE - The high citrate ion content ensures that citrate ions diffuse into the blood and act in the membrane filter as anticoagulants. The citrate ions are degraded in the body by the Krebs cycle. Citrate intoxication is prevented by ensuring that the content of free ionised Ca is low and the Ca2+ is continuously added to the blood after the dialysis. Thus the use of heparin is avoided.